Recent Press Releases

Sanofi : Sanofi successfully prices EUR 3 billion bond issue

Sanofi : Sanofi successfully prices EUR 3 billion bond issue Paris, France - September 4, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 3...

Roche announces change in Board of Directors

Roche announces change in Board of Directors Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D....

Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance

Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance NORTH CHICAGO, Illinois,...

Favourable Rulings, Upcoming Conferences, Clinical Study Results, Drug Availability, and Tender Offers - Research Reports on United Therapeutics, Illumina, AstraZeneca, Eli Lilly and Abbott

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 3, 2014<

Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes

- FreeStyle Libre System eliminates routine finger pricks for glucose measurements1 and requires no finger pricks for calibration

ABBOTT PARK, Ill.,

SANOFI PASTEUR'S DENGUE VACCINE CANDIDATE SUCCESSFULLY COMPLETES FINAL LANDMARK PHASE III CLINICAL EFFICACY STUDY IN LATIN AMERICA

- Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes - - Additional...

New England Governors urge HHS to reject Zohydro ER; Support Canadian action

New England Governors urge HHS to reject Zohydro ER; Support Canadian action Providence R.I. – Five New England Governors, including Rhode Island Governor Lincoln D. Chafee, this week called on...

Iroko Pharmaceuticals Announces Inclusion of ZORVOLEX® in Key 2015 National Formularies

Iroko Pharmaceuticals Announces Inclusion of ZORVOLEX® in Key 2015 National Formularies Over 50 million commercial lives covered in a preferred position PHILADELPHIA, September 3, 2014 —...

Teva Announces UK High Court Gives Positive Judgment in the Company's Patent Case Against AstraZeneca

Court Decision Invalidating AZ's Patent Supports Teva's Launch of DuoResp Spiromax® in UK JERUSALEM--(BUSINESS WIRE)--Sep. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA)...

Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 2, 2014<

Positive Drug Results, Market Activity Updates, Sustainability Report, Acquisitions, and Plant Closure - Research Reports on Repros, Jazz, Ingersoll-Rand, Nokia and Duke Energy

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, September 2, 2014<

Mexico first country to launch Ryzodeg®

Mexico first country to launch Ryzodeg® Bagsværd, Denmark, 1 September 2014 - Novo Nordisk today announced that in Mexico, as the first country in the world, Ryzodeg® is now launched...

Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 1, 2014-- Exelixis, Inc. (NASDAQ:EXEL) today announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of...

Cipla Enters the Respiratory Market in Germany and Sweden with Affordable High Quality Alternatives

MUMBAI, Sep 01, 2014 (PR Newswire Europe via COMTEX) -- MUMBAI, September 1, 2014 /PRNewswire/ -- Cipla, a global pharmaceutical company announces today the launch of Serroflo, its...

New Merck Headquarters Starts Taking Shape

New Merck Headquarters Starts Taking Shape - Groundbreaking for modular Innovation Center - New building in Darmstadt will further interdisciplinary and project-related collaboration to promote...

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

PISCATAWAY, N.J., Aug. 29, 2014 /PRNewswire/ -- InnoPharma, Inc.

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium -- including the University of Maryland School of Medicine and NIH -- now assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine<